Journal Article Summary
The article investigates the treatment patterns of two medications, tirzepatide and semaglutide, in patients with type 2 diabetes (T2D) who had not previously used glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Understanding how patients respond to these medications is important because adherence to diabetes treatments can lead to better blood sugar control and reduce the risk of complications. This study aims to provide insights into how often patients stick with their prescribed treatments and how these two medications compare in real-world settings.
The researchers conducted a retrospective cohort study using data from the Healthcare Integrated Research Database, focusing on patients who began treatment with either tirzepatide or semaglutide between May 2022 and May 2023. They included patients who had at least six months of continuous enrollment before starting treatment and analyzed their medication adherence and persistence over a 12-month period. The study found that patients starting tirzepatide had a higher number of medication fills compared to those starting semaglutide, indicating better adherence to the treatment.
However, the study has limitations, including its reliance on claims data, which may not capture all aspects of patient behavior or health outcomes. Additionally, the findings may not be generalizable to all populations, as the study participants were predominantly white and commercially insured. Patients should discuss these findings with their healthcare providers to understand how these medications might fit into their treatment plans and to ensure they are making informed choices about their diabetes management.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Hoog Meredith, Vallarino Carlos, Maldonado Juan M, Grabner Michael, Teng Chia-Chen, Terrell Kendra, Richard Emma. SAT-528 Real-world Treatment Patterns Of Tirzepatide Versus Semaglutide In GLP-1 RA-naive Patients With T2D. Journal of the Endocrine Society 2025. DOI: 10.1210/jendso/bvaf149.1060. PMCID: PMC12544560.
Featured Pill Pals Product
Tirzepatide --- 72 mg / 4 ml --- 4 ml vial --- Weight Loss Glucagon-Like Peptide-1 (GLP-1)
Tirzepatide — 72 mg / 4 ml — 4 ml vial — Weight Loss Glucagon-Like Peptide-1 (GLP-1) is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
